Vertex Pharma (VRTX) Announce Positive Results for Two Ph3 Studies of Tezacaftor/Ivacaftor Combination Treatments
Tweet Send to a Friend
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) today announced results from two Phase 3 studies of the tezacaftor (VX-661) / ivacaftor combination ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE